May. 13 at 8:03 PM
$KZR Kezar Life Sciences reports Q1 EPS (
$2.27), consensus (
$2.65)
Cash, cash equivalents and marketable securities totaled
$114.4 million as of March 31, 2025, compared to
$132.2 million as of December 31, 2024. The decrease was primarily attributable to cash used in operations. "We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH," said Chris Kirk, CEO and co-founder of Kezar. "There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies.
We are encouraged by the promising safety and efficacy data in this difficult-to-treat patient population, in particular the durable and steroid-sparing remissions observed in patients treated with zetomipzomib. We continue to respond to the FDA Division of Hepatology and Nutrition on the partial clinical hold and are working toward achieving alignment on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH."
